Significance of the metastasis-inducing protein AGR2 for outcome in hormonally treated breast cancer patients

The anterior gradient protein-2 (AGR2) is inducible by oestrogen and itself can induce metastasis in a rat model for breast cancer. Here, a rabbit antibody to recombinant human AGR2 was used to assess its prognostic significance in a retrospective cohort of 351 breast cancer patients treated by adjuvant hormonal therapy. The antibody stains 66% of breast carcinomas to varying degrees. The percentage of positive carcinoma cells in tumours directly correlates with the level of AGR2 mRNA (Spearman's rank correlation, P=0.0007) and protein (linear regression analysis r2=0.95, P=0.0002). There is a significant association of staining of carcinomas for AGR2 with oestrogen receptor α (ERα) staining and with low histological grade (both Fisher's Exact test P<0.0001). In the ERα-positive cases, but not the ERα-negative cases, when subdivided into the separate staining classes for AGR2, there is a significantly progressive decrease in patient survival with increased staining (log rank test, P=0.006). The significant association of staining for AGR2 with patient death over a 10-year period (log rank test P=0.007, hazard ratio=3) only becomes significant at 6 years of follow-up. This may be due to the cessation of adjuvant hormonal therapy at an earlier time, resulting in adverse re-expression of the metastasis-inducing protein AGR2.

[1]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[2]  R. Clarke,et al.  The process of malignant progression in human breast cancer. , 1990, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  A. Long,et al.  A human cell line from a pleural effusion derived from a breast carcinoma. , 1973, Journal of the National Cancer Institute.

[4]  R. Weigel,et al.  hAG-2, the human homologue of the Xenopus laevis cement gland gene XAG-2, is coexpressed with estrogen receptor in breast cancer cell lines. , 1998, Biochemical and biophysical research communications.

[5]  J. Winstanley,et al.  Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. , 2002, Cancer research.

[6]  P. Rudland,et al.  Osteopontin expression correlates with adhesive and metastatic potential in metastasis-inducing DNA-transfected rat mammary cell lines , 2004, British Journal of Cancer.

[7]  P. Rudland,et al.  Differential Modulation of Transcriptional Activity of Estrogen Receptors by Direct Protein-Protein Interactions with the T Cell Factor Family of Transcription Factors* , 2001, The Journal of Biological Chemistry.

[8]  N. Brünner,et al.  Hormone resistance, invasiveness, and metastatic potential in breast cancer , 1993, Breast Cancer Research and Treatment.

[9]  S. Leinster,et al.  Comparative expression of fibroblast growth factor mRNAs in benign and malignant breast disease. , 1994, British Journal of Cancer.

[10]  M. Schenker,et al.  hAG-2 and hAG-3, human homologues of genes involved in differentiation, are associated with oestrogen receptor-positive breast tumours and interact with metastasis gene C4.4a and dystroglycan , 2003, British Journal of Cancer.

[11]  C. Kamby.  The pattern of metastases in human breast cancer: methodological aspects and influence of prognostic factors. , 1990, Cancer treatment reviews.

[12]  Dong Liu,et al.  Human homologue of cement gland protein, a novel metastasis inducer associated with breast carcinomas. , 2005, Cancer research.

[13]  R. Gray,et al.  Annual hazard rates of recurrence for breast cancer after primary therapy. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  B. Gusterson,et al.  Isolation and properties of cell lines from the metastasising rat mammary tumour SMT-2A. , 1989, British Journal of Cancer.

[15]  J. Winstanley,et al.  Prognostic significance of the metastasis-inducing protein S100A4 (p9Ka) in human breast cancer. , 2000, Cancer research.

[16]  Douglas G. Altman,et al.  Practical statistics for medical research , 1990 .

[17]  A. Oates,et al.  The identification of osteopontin as a metastasis-related gene product in a rodent mammary tumour model. , 1996, Oncogene.

[18]  S. Kharbanda,et al.  Transfected MCF-7 cells as a model for breast cancer progression , 2004, Breast Cancer Research and Treatment.

[19]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[20]  A. Shaaban,et al.  Wild-type oestrogen receptor beta (ERβ1) mRNA and protein expression in Tamoxifen-treated post-menopausal breast cancers , 2004, British Journal of Cancer.

[21]  Catherine Legrand.  1687Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials : Early Breast Cancer Trialists' Collaborative Group (EBCTCG) , 2005 .

[22]  S. Leinster,et al.  Examining the technique of angiogenesis assessment in invasive breast cancer. , 1997, British Journal of Cancer.

[23]  P. Rudland,et al.  Induction of the metastatic phenotype by transfection of a benign rat mammary epithelial cell line with the gene for p9Ka, a rat calcium-binding protein, but not with the oncogene EJ-ras-1. , 1993, Oncogene.

[24]  J. Winstanley,et al.  Comparison of the metastasis‐inducing protein S100A4 (p9ka) with other prognostic markers in human breast cancer , 2000, International journal of cancer.

[25]  S. Leinster,et al.  Association of S100A4 and osteopontin with specific prognostic factors and survival of patients with minimally invasive breast cancer. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.